If you've ever found yourself feeling increasingly drawn to a stock that's constantly rising in price, you are not alone... Since the dawn of the stock market, speculators have been captured by the tendency of prices to 'trend'. When...
BVXV — Biondvax Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareSpeculativeMicro CapMomentum Trap
- $22.17m
- $28.75m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.72 | ||
| Price to Tang. Book | 4.72 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -41.77% | ||
| Return on Equity | -222.91% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ILSm | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for BVXV
Anyone familiar with stock market screeners will know that shares in Biondvax Pharmaceuticals (NAQ:BVXV) have been in an uptrend in recent months, with strong relative price strength on a 1-month, 6-month and 12-month basis.Finding sto...
Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a very profitable strategy. In fact, many academics now...
Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a very profitable strategy. In fact, many academics now...
Despite the market volatility, shares in Biondvax Pharmaceuticals (NAQ:BVXV) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to br...
Profile Summary
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
Directors
- Last Annual
- December 31st, 2021
- Last Interim
- March 31st, 2022
- Incorporated
- July 22nd, 2003
- Public Since
- July 7th, 2007
- No. of Employees
- 17
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 745,048,544
- Address
- Jerusalem Biopark, JERUSALEM, 00000
- Web
- http://www.biondvax.com
- Phone
- +972 89302529
- Contact
- Joshua Phillipson
- Auditors
- Kost, Forer, Gabbay & Kasierer
Upcoming Events for BVXV
Similar to BVXV
180 Life Sciences
NASDAQ Capital Market
9 Meters Biopharma
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Biondvax Pharmaceuticals share price?
As of Today at 13:03 UTC, shares in Biondvax Pharmaceuticals are trading at $1.19. This share price information is delayed by 15 minutes.
How has the Biondvax Pharmaceuticals share price performed this year?
Shares in Biondvax Pharmaceuticals last closed at $1.19 and the price had moved by -61.36% over the past 365 days. In terms of relative price strength the Biondvax Pharmaceuticals share price has underperformed the S&P500 Index by -55.58% over the past year.
What are the analyst and broker recommendations for Biondvax Pharmaceuticals?
The overall consensus recommendation for Biondvax Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Biondvax Pharmaceuticals dividend yield?
Biondvax Pharmaceuticals does not currently pay a dividend.
Does Biondvax Pharmaceuticals pay a dividend?
Biondvax Pharmaceuticals does not currently pay a dividend.
When does Biondvax Pharmaceuticals next pay dividends?
Biondvax Pharmaceuticals does not currently pay a dividend.
How do I buy Biondvax Pharmaceuticals shares?
To buy shares in Biondvax Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Biondvax Pharmaceuticals?
As of the previous close price of $1.19, shares in Biondvax Pharmaceuticals had a market capitalisation of $22.17m.
Where are Biondvax Pharmaceuticals shares listed?
Here are the trading details for Biondvax Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: BVXV
What kind of share is Biondvax Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Biondvax Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Biondvax Pharmaceuticals share price forecast for 2022?
The analyst consensus target price for shares in Biondvax Pharmaceuticals is $380.00. That is 31832.77% above the last closing price of $1.19.
Analysts covering Biondvax Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -ILS1.43 for the next financial year.
What is the trend in the Biondvax Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biondvax Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +0.02%.
As of the last closing price of $1.19, shares in Biondvax Pharmaceuticals were trading -30.87% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Biondvax Pharmaceuticals PE Ratio?
The Biondvax Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Biondvax Pharmaceuticals?
We do not have data on Biondvax Pharmaceuticals' directors